ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

3 Top Dividend Stocks Analysts Are Bullish on Right Now

High-Yield Dividend Stocks Analyst Ratings - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.

We’re at the end of earnings season. That means it’s time for analysts to weigh in on the outlook for specific stocks. While there’s cautious optimism about how the second half of the year will go, the outlook for the current quarter may still be tricky for investors to navigate.

Many investors look at analysts' estimates to help maintain a long-term outlook. These individuals typically work for investment banks, brokerages, or investment management firms. They have access to information, including access to company insiders, that retail investors lack. They use this to assign ratings and price targets to their assigned stocks.

Not surprisingly, the largest companies receive the most analyst coverage. These companies have large institutional ownership, which means a company’s stock is widely held in 401(k) plans and other ETFs.

Analysts will usually wait a day or so after a company reports earnings to issue a rating and/or price target. When they do, it can cause a strong move in these stocks.

Here are three blue-chip companies with strong analyst support that should support a higher stock price.

Johnson & Johnson Has Become Too Cheap to Ignore

[content-module:DividendStats|NYSE: JNJ]

It might surprise some investors to see Johnson & Johnson (NYSE: JNJ) on this list. The stock has delivered a negative total return of around 4.1% in the last three years. That’s due in no small part to the legal battles that are still with the company even as it spun off its consumer products division into Kenvue Inc. (NYSE: KVUE).

However, investors are intrigued by what’s left of the company. The company’s Innovative Medicine segment has several drugs in clinical-stage trials. This includes areas like oncology, immunology, and neurology. It's also considered to be a leader in precision medicine, which seeks to find individualized treatments based on a patient’s genetic profile.

The long-term payoff may still be years away. However, analysts seem to like what they see here and now. JNJ stock is up 6.2% this year, outpacing the broader market. In May, the stock broke a bearish pattern of making lower highs and lower lows, and the stock price seems to be finding a higher level of support around $150.

With a forward price-to-earnings (P/E) ratio of around 14.3x, the stock is trading at a discount to its three- and five-year averages. Analysts have a consensus price target of $170.88 on JNJ stock, which gives investors 11% upside in addition to a rock-solid dividend that yields 3.38% as of June 4.

It's Still a Good Time to Buy the Dip on This Big Oil Stock

[content-module:DividendStats|NYSE: XOM]

Energy stocks have lagged the market in 2025. Investors may have misinterpreted what the Trump administration’s energy agenda was going to do to the price of oil. That’s currently in the low $60 range, and some industry observers believe it will go into the $50s and maybe lower if the economy continues to lose steam.

Assuming that bear case, Exxon Mobil Corp. (NYSE: XOM) remains a solid buy. That’s because the company has outlined its efforts to raise its breakeven costs to the mid-$30 range by 2027. The breakeven cost is the cost at which it remains profitable to extract oil.

However, taking an optimistic view of the Trump administration’s long-term agenda suggests stronger industrial activity, which would, at the very least, put a floor on oil prices. That would mean long-term investors should be less concerned about the XOM stock floor and position themselves to capitalize on what higher crude oil prices will mean for the stock.

Analysts are maintaining a consensus price target of $125.50. That gives investors about 22% upside in the stock price. That goes along with a dividend that has a dividend yield of 3.26%.

Home Depot Isn’t the Fixer Upper Some May Think

[content-module:DividendStats|NYSE: HD]

Home Depot (NYSE: HD) is down 3.6% in 2025 and acknowledged that consumers are holding off on big projects. However, the April housing data from the U.S. Census Bureau isn’t as bleak as it may seem. New home sales reached a multi-year high annualized pace of 743,000 units.

Analysts also believe that HD stock will get back to growth with more clarity around tariffs. That would support Harvard University’s Leading Indicator of Remodeling (LIRA) index that points to 2.5% growth in remodeling and home-upgrade outlays through the first quarter of 2026.

HD stock appears to have formed a bottom in April and has been in a bullish pattern that was supported by better-than-expected earnings. Analysts have a consensus price target of $426.77 on the stock, which is a 13.8% upside to go along with a dividend that has increased at an average annualized rate of over 10% over the last three years and currently yields 2.45%.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.